Endocrine therapy for advanced/metastatic breast cancer.
about
Risk-reducing medication for primary breast cancer: a network meta-analysisOptimal management of hormone receptor positive metastatic breast cancer in 2016Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitorsOne-pot synthesis of cinnamylideneacetophenones and their in vitro cytotoxicity in breast cancer cellsEndocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausalCircadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cellsOvercoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 InhibitorsAnnexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.Targeted therapy: resistance and re-sensitization.Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review.
P2860
Q24185817-E38D7564-FF22-4DC5-97C7-3D7F45D365A8Q26777683-456CD3C9-BC58-4643-B37E-0F6641C04D78Q26830522-C7B077D8-1D29-4623-B849-4ED83BE12DEFQ34094228-CEE8C6AA-B83A-4D62-97D5-E59972F6DC61Q34611634-C13DBDEA-93D1-4375-8613-0E0B62DB1B21Q35747766-7FB0F238-E10B-4FE8-B727-A4A6E07A4113Q36280127-8FFD9B8E-3568-499A-BE54-C89CF3DD0677Q36420373-DB411734-2CBE-4E8F-8B51-0E6F9AB2C127Q36772047-E6F41286-60F0-4D66-B562-81598EC31E35Q36836599-009DDF81-8105-4B3B-B8AD-6D27E7529DF8Q41356511-2F58CB90-1F28-479F-AF71-3C3285620F8BQ48125385-ED01D08E-9486-43A2-9FDB-530A6B91F807Q55427632-E640F989-7978-44F2-9165-28A15107BD6D
P2860
Endocrine therapy for advanced/metastatic breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Endocrine therapy for advanced/metastatic breast cancer.
@en
type
label
Endocrine therapy for advanced/metastatic breast cancer.
@en
prefLabel
Endocrine therapy for advanced/metastatic breast cancer.
@en
P1476
Endocrine therapy for advanced/metastatic breast cancer.
@en
P2093
Gaia Schiavon
Ian E Smith
P304
715-36, viii
P356
10.1016/J.HOC.2013.05.004
P577
2013-06-18T00:00:00Z